Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Intellia Therapeutics, Inc. (NTLA)
USD12.92
-0.38 (-2.85%)
US NASDAQ Healthcare Biotechnology
Address
40 Erie Street 2139
Cambridge, MA, US
Cambridge, MA, US
CEO
John Leonard
Website
intelliatx.com
IPO
2016-05-06
CIK 1652130 ISIN US45826J1051
Also trades on
London Stock Exchange · 0JBU.L (USD)
NASDAQ Global Market · NTLA (USD)
Description
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
News Sentiment (7d)
3 articles
- NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock? Zacks Investment Research
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewsWire
- A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics The Motley Fool
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD12.92
-0.38 (-2.85%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
7M
Beta
1.82
Float Shares
111.85M
Free Float %
94.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.34% | +8.91% | +6.89% | +20.17% | +41.65% | +60.40% | +68.65% | -67.68% | -78.21% | -42.89% | -34.75% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (39 ratings, all time)
Buy
Price Targets & DCF
Current price
12.92
Low
13.00
+0.6%
Consensus
23.60
+82.6%
Median
25.00
+93.5%
High
35.00
+170.9%
Ratings Trend (MoM)
54% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | -1 |
| Buy | 12 | -1 |
| Hold | 9 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 1 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 4 |
23.25
+79.9%
|
| Last Quarter | 4 |
23.25
+79.9%
|
| Last Year | 21 |
20.29
+57.0%
|
| All Time | 50 |
71.68
+454.8%
|
Quality scores
Altman Z-Score
1.66
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+16.9% ★ Q1'26: -9.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+27.4% Q1'26: +26.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-703.9% Q1'26: -780.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-609.9% Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-131.1% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+9.6% Q1'26: +14.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.24×
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 18 Rev. Ana. 17 EPS Ana. |
Dec 2027 16 Rev. Ana. 16 EPS Ana. |
Dec 2028 15 Rev. Ana. 13 EPS Ana. |
Dec 2029 11 Rev. Ana. 11 EPS Ana. |
Dec 2030 7 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
16.48M
est: 16.43M (+0.3%)
|
26.12M
est: 27.22M (-4.0%)
|
30.43M
est: 31.37M (-3.0%)
|
43.10M
est: 42.08M (+2.4%)
|
57.99M
est: 66.73M (-13.1%)
|
33.05M
est: 29.16M (+13.4%)
|
52.12M
est: 51.90M (+0.4%)
|
36.28M
est: 45.97M (-21.1%)
|
57.88M
est: 53.93M (+7.3%)
|
67.67M
est: 56.58M (+19.6%)
|
59.61M
37.64M – 86.84M
+5.3% YoY
|
259.25M
2.47M – 2.04B
+334.9% YoY
|
643.86M
46.47M – 5.62B
+148.4% YoY
|
1.57B
113.60M – 13.73B
+144.4% YoY
|
2.68B
193.48M – 23.39B
+70.3% YoY
|
| EBITDA |
-31.06M
est: -16.43M (-89.0%)
|
-66.56M
est: -27.22M (-144.5%)
|
-86.41M
est: -86.87M (+0.5%)
|
-100.78M
est: -103.26M (+2.4%)
|
-130.27M
est: -117.12M (-11.2%)
|
-260.96M
est: -224.78M (-16.1%)
|
-450.59M
est: -243.85M (-84.8%)
|
-506.32M
est: -45.97M (-1,001.5%)
|
-523.98M
est: -53.93M (-871.6%)
|
-396.77M
est: -56.58M (-601.2%)
|
-59.61M
-86.84M – -37.64M
-5.3% YoY
|
-259.25M
-2.04B – -2.47M
-334.9% YoY
|
-643.86M
-5.62B – -46.47M
-148.4% YoY
|
-1.57B
-13.73B – -113.60M
-144.4% YoY
|
-2.68B
-23.39B – -193.48M
-70.3% YoY
|
| EBIT |
-32.16M
est: -16.43M (-95.7%)
|
-69.56M
est: -27.22M (-155.5%)
|
-90.87M
est: -97.71M (+7.0%)
|
-106.37M
est: -117.01M (+9.1%)
|
-136.58M
est: -124.90M (-9.4%)
|
-267.85M
est: -230.76M (-16.1%)
|
-458.16M
est: -252.76M (-81.3%)
|
-515.29M
est: -45.97M (-1,021.0%)
|
-534.26M
est: -53.93M (-890.7%)
|
-412.69M
est: -56.58M (-629.4%)
|
-59.61M
-86.84M – -37.64M
-5.3% YoY
|
-259.25M
-2.04B – -2.47M
-334.9% YoY
|
-643.86M
-5.62B – -46.47M
-148.4% YoY
|
-1.57B
-13.73B – -113.60M
-144.4% YoY
|
-2.68B
-23.39B – -193.48M
-70.3% YoY
|
| Net Income |
-31.63M
est: -94.57M (+66.5%)
|
-67.54M
est: -163.67M (+58.7%)
|
-85.34M
est: -91.71M (+6.9%)
|
-99.53M
est: -109.41M (+9.0%)
|
-134.23M
est: -123.01M (-9.1%)
|
-267.89M
est: -230.77M (-16.1%)
|
-474.19M
est: -453.44M (-4.6%)
|
-481.19M
est: -508.80M (+5.4%)
|
-519.02M
est: -569.15M (+8.8%)
|
-412.69M
est: -412.69M (+0.0%)
|
-432.18M
-530.10M – -213.80M
-4.7% YoY
|
-265.25M
-585.18M – 2.07B
+38.6% YoY
|
-155.36M
-397.32M – 1.53B
+41.4% YoY
|
353.63M
-72.91M – 3.90B
+327.6% YoY
|
922.66M
-190.23M – 10.19B
+160.9% YoY
|
| SGA |
16.80M
est: 32.97M (-49.0%)
|
28.03M
est: 54.61M (-48.7%)
|
32.19M
est: 62.94M (-48.9%)
|
41.06M
est: 84.42M (-51.4%)
|
44.17M
est: 40.95M (+7.9%)
|
71.10M
est: 58.49M (+21.5%)
|
90.31M
est: 104.12M (-13.3%)
|
116.50M
est: 101.49M (+14.8%)
|
125.83M
est: 119.07M (+5.7%)
|
119.80M
est: 124.92M (-4.1%)
|
131.60M
83.09M – 191.73M
+5.3% YoY
|
572.39M
5.46M – 4.51B
+334.9% YoY
|
1.42B
102.60M – 12.40B
+148.4% YoY
|
3.48B
250.81M – 30.31B
+144.4% YoY
|
5.92B
427.19M – 51.63B
+70.3% YoY
|
| EPS |
-0.91
est: -0.96 (+4.9%)
|
-1.88
est: -1.66 (-13.5%)
|
-1.98
est: -2.11 (+6.1%)
|
-1.96
est: -2.10 (+6.5%)
|
-2.40
est: -2.28 (-5.3%)
|
-3.78
est: -3.60 (-4.9%)
|
-6.16
est: -6.16 (+0.0%)
|
-5.42
est: -5.48 (+1.0%)
|
-5.25
est: -5.31 (+1.2%)
|
-3.81
est: -3.98 (+4.2%)
|
-3.56
-4.89 – -1.97
+10.5% YoY
|
-2.07
-5.40 – 19.10
+41.7% YoY
|
-1.01
-3.67 – 14.11
+51.3% YoY
|
3.26
-0.67 – 36.02
+422.8% YoY
|
8.51
-1.76 – 93.99
+160.9% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-28 | Canaccord Genuity | Buy | Buy | Maintain |
| 2026-04-27 | Baird | Neutral | Neutral | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-312.32M
OE per share TTM
-2.81
Owner's Yield
-18.28%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
250.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
119
Total invested
166.37M
Insider transactions (90d)
0
Beneficial owners (>5%)
17
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 7.25M | 8.70% | 7.07M | — | 7.25M | — | HC | Delaware | 2023-01-25 | ↗ |
| 2 | ARK Investment Management LLC | 6.80M | 15.67% | 5.45M | 383.3K | 5.45M | 1.35M | IA | Delaware, United States | 2019-02-14 | ↗ |
| 3 | The Vanguard Group - 23-1945930 | 6.44M | 8.66% | — | 132.4K | 6.25M | 191.2K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 4 | Biosciences, Inc. | 5.59M | 15.50% | — | 5.59M | — | — | HC | Delaware | 2017-02-28 | ↗ |
| 5 | Therapeutics Holdco, LLC | 5.59M | 15.50% | — | 5.59M | — | — | OO | Delaware | 2017-02-28 | ↗ |
| 6 | REGENERON PHARMACEUTICALS, INC. 13-3444607 | 3.70M | 4.98% | 3.70M | — | 3.70M | — | CO | New York | 2022-02-11 | ↗ |
| 7 | Regeneron Pharmaceuticals, Inc. | 2.78M | 7.70% | 2.78M | — | 2.78M | — | CO | New York | 2016-05-11 | ↗ |
| 8 | Nikko Asset Management Americas, Inc. | 2.75M | 3.70% | — | 2.31M | — | 2.75M | IA | USA | 2022-02-14 | ↗ |
| 9 | Nikko Asset Management Co., Ltd. (“NAM”) | 2.75M | 3.70% | — | 2.75M | — | — | FI, IA, HC | Japan | 2022-02-04 | ↗ |
| 10 | Sumitomo Mitsui Trust Holdings, Inc. (“SMTH”) | 2.75M | 3.70% | — | 2.75M | — | — | FI, HC | Japan | 2022-02-04 | ↗ |
| 11 | OrbiMed Advisors LLC | 2.66M | 7.40% | — | 2.66M | — | 10.00 | IA | Delaware | 2016-05-20 | ↗ |
| 12 | Samuel D. Isaly | 2.66M | 7.40% | — | 2.66M | — | 10.00 | IN | United States | 2016-05-20 | ↗ |
| 13 | OrbiMed Capital GP V LLC | 2.04M | 5.66% | — | 2.04M | — | 10.00 | OO | Delaware | 2016-05-20 | ↗ |
| 14 | STATE STREET CORPORATION | 1.69M | 3.46% | — | 1.55M | — | 1.69M | HC | BOSTON, MASSACHUSETTS | 2020-02-13 | ↗ |
| 15 | OrbiMed Global Healthcare GP LLC | 623.3K | 1.73% | — | 623.3K | — | 10.00 | OO | Delaware | 2016-05-20 | ↗ |
| 16 | BRONCO (BARCLAYS CAYMAN) LIMITED | — | 0.00% | 66.2K | 1.2K | 2.68M | 65.5K | — | Pennsylvania | 2019-02-11 | ↗ |
| 17 | Sumitomo Mitsui Trust Bank, Limited (“SMTB”) | — | 0.00% | — | — | — | — | BK, FI | Japan | 2019-08-08 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
119
-197 vs prev Q
New positions
19
Closed positions
196
Increased
69
Reduced
19
Put/Call ratio
0.00
Calls held
702.8K
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ARK INVESTMENT MANAGEMENT LLC | 14.21M +2.3M (+19.2%) | 127.72M -78.1M (-38.0%) | 12.89% +2.077 pp | 0.85% -0.378 pp | USD30.58 -70.6% | 37 qtrs — |
| 2 | VANGUARD GROUP INC | 13.01M +2.0M (+17.8%) | 116.96M -73.8M (-38.7%) | 11.81% +1.784 pp | 0.00% -0.001 pp | USD32.57 -72.4% | 39 qtrs — |
| 3 | BLACKROCK, INC. | 10.28M +1.0M (+10.8%) | 92.39M -67.8M (-42.3%) | 9.33% +0.909 pp | 0.00% -0.001 pp | USD18.62 -51.7% | 6 qtrs — |
| 4 | STATE STREET CORP | 6.42M +1.4M (+29.1%) | 57.71M -28.1M (-32.8%) | 5.83% +1.314 pp | 0.00% -0.001 pp | USD26.65 -66.3% | 39 qtrs — |
| 5 | D. E. SHAW & CO., INC. | 5.33M +3.1M (+139.2%) | 47.93M +9.4M (+24.5%) | 4.84% +2.816 pp | 0.03% +0.005 pp | USD11.26 -20.2% | 6 qtrs — |
| 6 | REGENERON PHARMACEUTICALS, INC. | 3.70M +— (+0.0%) | 33.29M -30.7M (-47.9%) | 3.36% +0.000 pp | 98.49% +89.363 pp | USD11.66 -22.9% | 5 qtrs — |
| 7 | TWO SIGMA INVESTMENTS, LP | 2.70M +249.1K (+10.2%) | 24.26M -18.0M (-42.7%) | 2.45% +0.226 pp | 0.03% -0.029 pp | USD17.33 -48.1% | 29 qtrs — |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.70M +107.3K (+4.1%) | 24.24M -20.5M (-45.8%) | 2.45% +0.097 pp | 0.00% -0.001 pp | USD38.74 -76.8% | 39 qtrs — |
| 9 | TWO SIGMA ADVISERS, LP | 2.35M +182.9K (+8.5%) | 21.09M -16.3M (-43.5%) | 2.13% +0.166 pp | 0.04% -0.034 pp | USD21.34 -57.9% | 29 qtrs — |
| 10 | MORGAN STANLEY | 2.33M -3.7M (-61.3%) | 20.93M -83.1M (-79.9%) | 2.11% -3.353 pp | 0.00% -0.005 pp | USD32.46 -72.3% | 39 qtrs — |
| 11 | SUMITOMO MITSUI TRUST HOLDINGS, INC. | 2.19M -162.4K (-6.9%) | 19.71M -21.0M (-51.5%) | 1.99% -0.147 pp | 0.01% -0.012 pp | USD32.25 -72.1% | 28 qtrs — |
| 12 | NIKKO ASSET MANAGEMENT AMERICAS, INC. | 2.19M -162.4K (-6.9%) | 19.69M -20.9M (-51.5%) | 1.99% -0.147 pp | 0.23% -0.166 pp | USD33.08 -72.8% | 30 qtrs — |
| 13 | DIMENSIONAL FUND ADVISORS LP | 1.93M +174.6K (+9.9%) | 17.37M -13.0M (-42.8%) | 1.75% +0.158 pp | 0.00% -0.003 pp | USD26.03 -65.5% | 30 qtrs — |
| 14 | FMR LLC | 1.76M -92.4K (-5.0%) | 15.82M -16.2M (-50.5%) | 1.60% -0.084 pp | 0.00% -0.001 pp | USD41.50 -78.3% | 39 qtrs — |
| 15 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 1.74M +127.2K (+7.9%) | 15.62M -12.2M (-43.8%) | 1.58% +0.116 pp | 0.05% -0.038 pp | USD15.73 -42.8% | 22 qtrs — |
| 16 | RENAISSANCE TECHNOLOGIES LLC | 1.67M +1.0M (+156.9%) | 15.04M +3.8M (+33.8%) | 1.52% +0.927 pp | 0.02% +0.009 pp | USD9.14 -1.6% | 9 qtrs — |
| 17 | GOLDMAN SACHS GROUP INC | 1.46M -2.8M (-66.0%) | 13.09M -60.8M (-82.3%) | 1.32% -2.562 pp | 0.00% -0.007 pp | USD20.44 -56.0% | 39 qtrs — |
| 18 | BANK OF AMERICA CORP /DE/ | 1.24M +636.9K (+105.2%) | 11.17M +711.5K (+6.8%) | 1.13% +0.544 pp | 0.00% +0.000 pp | USD16.04 -44.0% | 39 qtrs — |
| 19 | ARMISTICE CAPITAL, LLC | 1.16M +484.0K (+72.0%) | 10.39M -1.2M (-10.5%) | 1.05% +0.439 pp | 0.12% -0.049 pp | USD8.65 +3.9% | 4 qtrs — |
| 20 | JUPITER ASSET MANAGEMENT LTD | 1.04M -323.9K (-23.8%) | 9.33M -14.2M (-60.3%) | 0.94% -0.294 pp | 0.07% -0.127 pp | USD17.27 -47.9% | 2 qtrs — |
| 21 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 945.8K +72.6K (+8.3%) | 8.50M -6.6M (-43.6%) | 0.86% +0.066 pp | 0.00% -0.001 pp | USD47.27 -81.0% | 39 qtrs — |
| 22 | STIFEL FINANCIAL CORP | 931.4K +152.9K (+19.6%) | 8.37M -5.1M (-37.7%) | 0.85% +0.139 pp | 0.01% -0.005 pp | USD12.05 -25.4% | 21 qtrs — |
| 23 | NORTHERN TRUST CORP | 872.6K -33.7K (-3.7%) | 7.84M -7.8M (-49.9%) | 0.79% -0.031 pp | 0.00% -0.001 pp | USD35.68 -74.8% | 39 qtrs — |
| 24 | HRT FINANCIAL LP | 764.9K +764.9K (+100.0%) | 6.88M +6.9M (+100.0%) | 0.69% +0.694 pp | 0.02% +0.022 pp | USD8.99 +0.0% | 5 qtrs — |
| 25 | CITADEL ADVISORS LLC | 754.6K +379.5K (+101.2%) | 6.78M +305.9K (+4.7%) | 0.68% +0.344 pp | 0.00% +0.000 pp | USD15.74 -42.9% | 34 qtrs — |
| 26 | JPMORGAN CHASE & CO | 743.7K +303.1K (+68.8%) | 6.69M -922.8K (-12.1%) | 0.67% +0.250 pp | 0.00% +0.000 pp | USD24.51 -63.3% | 33 qtrs — |
| 27 | IQ EQ FUND MANAGEMENT (IRELAND) LTD | 731.4K +237.0K (+47.9%) | 6.58M -2.0M (-23.0%) | 0.66% +0.215 pp | 0.45% -0.125 pp | USD11.74 -23.4% | 7 qtrs — |
| 28 | CONTRARIUS GROUP HOLDINGS LTD | 714.5K -5.2M (-87.9%) | 6.42M -95.3M (-93.7%) | 0.65% -4.697 pp | 0.31% -4.293 pp | USD15.19 -40.8% | 5 qtrs — |
| 29 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 699.8K +390.2K (+126.0%) | 6.29M +944.4K (+17.7%) | 0.64% +0.354 pp | 0.00% +0.000 pp | USD13.18 -31.8% | 35 qtrs — |
| 30 | MAREX GROUP PLC | 623.6K +1.0K (+0.2%) | 5.61M -5.1M (-47.9%) | 0.57% +0.001 pp | 0.04% -0.041 pp | USD9.38 -4.2% | 3 qtrs — |
| 31 | BNP PARIBAS ARBITRAGE, SNC | 591.3K +541.0K (+1,076.6%) | 5.32M +4.4M (+512.5%) | 0.54% +0.491 pp | 0.00% +0.002 pp | USD9.89 -9.1% | 39 qtrs — |
| 32 | HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 578.6K +13.4K (+2.4%) | 5.20M -4.6M (-46.7%) | 0.53% +0.012 pp | 0.32% -0.278 pp | USD92.22 -90.3% | 20 qtrs — |
| 33 | BARCLAYS PLC | 511.2K +218.4K (+74.6%) | 4.60M -1.4M (-23.6%) | 0.46% +0.182 pp | 0.00% 0.000 pp | USD17.60 -48.9% | 39 qtrs — |
| 34 | VESTMARK ADVISORY SOLUTIONS, INC. | 443.9K +146.4K (+49.2%) | 3.99M -1.1M (-22.3%) | 0.40% +0.133 pp | 0.05% -0.044 pp | USD15.05 -40.3% | 9 qtrs — |
| 35 | WELLS FARGO & COMPANY/MN | 433.7K -106.1K (-19.6%) | 3.90M -5.4M (-58.2%) | 0.39% -0.096 pp | 0.00% -0.001 pp | USD21.32 -57.8% | 39 qtrs — |
| 36 | INVESCO LTD. | 433.3K +23.9K (+5.8%) | 3.90M -3.2M (-44.9%) | 0.39% +0.022 pp | 0.00% -0.001 pp | USD18.60 -51.7% | 28 qtrs — |
| 37 | RAYMOND JAMES FINANCIAL INC | 401.7K +84.7K (+26.7%) | 3.61M -1.9M (-34.0%) | 0.36% +0.077 pp | 0.00% -0.001 pp | USD11.07 -18.8% | 5 qtrs — |
| 38 | UBS GROUP AG | 378.2K -117.7K (-23.7%) | 3.40M -5.2M (-60.3%) | 0.34% -0.107 pp | 0.00% -0.001 pp | USD13.44 -33.1% | 3 qtrs — |
| 39 | FEDERATED HERMES, INC. | 354.9K +351.7K (+10,777.9%) | 3.19M +3.1M (+5,562.6%) | 0.32% +0.319 pp | 0.01% +0.005 pp | USD9.22 -2.5% | 23 qtrs — |
| 40 | JANE STREET GROUP, LLC | 348.6K +322.8K (+1,251.2%) | 3.13M +2.7M (+603.4%) | 0.32% +0.293 pp | 0.00% +0.000 pp | USD9.77 -8.0% | 6 qtrs — |
| 41 | PEAK6 LLC | 346.7K +2.8K (+0.8%) | 3.12M -2.8M (-47.5%) | 0.31% +0.003 pp | 0.01% -0.003 pp | USD13.94 -35.5% | 5 qtrs — |
| 42 | DIADEMA PARTNERS LP | 316.9K +316.9K (+100.0%) | 2.85M +2.8M (+100.0%) | 0.29% +0.288 pp | 0.49% +0.491 pp | USD8.99 +0.0% | 1 qtrs NEW |
| 43 | BIRCHVIEW CAPITAL, LP | 315.4K +255.4K (+425.7%) | 2.84M +1.8M (+173.6%) | 0.29% +0.232 pp | 1.66% +0.878 pp | USD9.06 -0.8% | 3 qtrs — |
| 44 | HUDSON BAY CAPITAL MANAGEMENT LP | 315.0K +85.0K (+37.0%) | 2.83M -1.1M (-28.7%) | 0.29% +0.064 pp | 0.01% -0.004 pp | USD19.51 -53.9% | 18 qtrs — |
| 45 | BANK OF NEW YORK MELLON CORP | 314.2K +1.2K (+0.4%) | 2.82M -2.6M (-47.8%) | 0.29% +0.001 pp | 0.00% -0.001 pp | USD53.05 -83.1% | 39 qtrs — |
| 46 | AQR CAPITAL MANAGEMENT LLC | 313.7K +103.3K (+49.1%) | 2.82M -813.6K (-22.4%) | 0.28% +0.094 pp | 0.00% -0.001 pp | USD10.97 -18.0% | 5 qtrs — |
| 47 | WASATCH ADVISORS LP | 313.7K +313.7K (+100.0%) | 2.82M +2.8M (+100.0%) | 0.28% +0.285 pp | 0.02% +0.017 pp | USD8.99 +0.0% | 1 qtrs NEW |
| 48 | FIRST TRUST ADVISORS LP | 276.9K +266.2K (+2,493.2%) | 2.49M +2.3M (+1,249.9%) | 0.25% +0.242 pp | 0.00% +0.002 pp | USD9.02 -0.3% | 3 qtrs — |
| 49 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 259.7K +259.7K (+100.0%) | 2.33M +2.3M (+100.0%) | 0.24% +0.236 pp | 0.01% +0.006 pp | USD8.99 +0.0% | 1 qtrs NEW |
| 50 | HEADLANDS TECHNOLOGIES LLC | 243.9K +184.3K (+309.1%) | 2.19M +1.2M (+112.9%) | 0.22% +0.167 pp | 0.18% +0.101 pp | USD10.92 -17.7% | 3 qtrs — |
| 51 | UBS ASSET MANAGEMENT AMERICAS INC | 239.2K -2.0K (-0.8%) | 2.15M -2.0M (-48.4%) | 0.22% -0.002 pp | 0.00% -0.001 pp | USD39.52 -77.3% | 27 qtrs — |
| 52 | GSA CAPITAL PARTNERS LLP | 233.1K +158.0K (+210.4%) | 2.10M +798.0K (+61.5%) | 0.21% +0.143 pp | 0.18% +0.072 pp | USD8.96 +0.3% | 7 qtrs — |
| 53 | NUVEEN, LLC | 232.7K +— (+0.0%) | 2.09M -1.9M (-47.9%) | 0.21% +0.000 pp | 0.00% -0.001 pp | USD7.11 +26.4% | 4 qtrs — |
| 54 | CITIGROUP INC | 231.2K +141.5K (+157.8%) | 2.08M +529.5K (+34.2%) | 0.21% +0.128 pp | 0.00% +0.000 pp | USD14.21 -36.7% | 39 qtrs — |
| 55 | BRIDGEWATER ASSOCIATES, LP | 223.2K +223.2K (+100.0%) | 2.01M +2.0M (+100.0%) | 0.20% +0.203 pp | 0.01% +0.007 pp | USD8.99 +0.0% | 1 qtrs NEW |
| 56 | QUADRATURE CAPITAL LTD | 216.0K +216.0K (+100.0%) | 1.94M +1.9M (+100.0%) | 0.20% +0.196 pp | 0.02% +0.020 pp | USD8.99 +0.0% | 4 qtrs — |
| 57 | RAFFERTY ASSET MANAGEMENT, LLC | 215.4K +32.3K (+17.7%) | 1.94M -1.2M (-38.8%) | 0.20% +0.029 pp | 0.01% -0.004 pp | USD32.12 -72.0% | 28 qtrs — |
| 58 | CAPITAL FUND MANAGEMENT S.A. | 202.0K +16.4K (+8.8%) | 1.82M -1.4M (-43.3%) | 0.18% +0.015 pp | 0.01% -0.003 pp | USD8.76 +2.6% | 10 qtrs — |
| 59 | SWISS NATIONAL BANK | 201.0K +10.3K (+5.4%) | 1.81M -1.5M (-45.1%) | 0.18% +0.009 pp | 0.00% -0.001 pp | USD45.83 -80.4% | 37 qtrs — |
| 60 | WOODLINE PARTNERS LP | 201.0K +— (+0.0%) | 1.81M -1.7M (-47.9%) | 0.18% +0.000 pp | 0.01% -0.009 pp | USD9.34 -3.7% | 6 qtrs — |
| 61 | AMERICAN CENTURY COMPANIES INC | 191.4K -58.8K (-23.5%) | 1.72M -2.6M (-60.2%) | 0.17% -0.053 pp | 0.00% -0.001 pp | USD45.49 -80.2% | 19 qtrs — |
| 62 | TUDOR INVESTMENT CORP ET AL | 189.1K +189.1K (+100.0%) | 1.70M +1.7M (+100.0%) | 0.17% +0.172 pp | 0.00% +0.003 pp | USD8.99 +0.0% | 10 qtrs — |
| 63 | HENNION & WALSH ASSET MANAGEMENT, INC. | 166.7K +16.3K (+10.9%) | 1.50M -1.1M (-42.3%) | 0.15% +0.015 pp | 0.05% -0.042 pp | USD13.89 -35.3% | 7 qtrs — |
| 64 | QUBE RESEARCH & TECHNOLOGIES LTD | 158.2K +158.2K (+100.0%) | 1.42M +1.4M (+100.0%) | 0.14% +0.144 pp | 0.00% +0.001 pp | USD8.99 +0.0% | 1 qtrs NEW |
| 65 | DEUTSCHE BANK AG\ | 153.5K +2.2K (+1.5%) | 1.38M -1.2M (-47.2%) | 0.14% +0.002 pp | 0.00% 0.000 pp | USD42.48 -78.8% | 39 qtrs — |
| 66 | PINNACLE ASSOCIATES LTD | 149.2K -14.5K (-8.8%) | 1.34M -1.5M (-52.5%) | 0.14% -0.013 pp | 0.02% -0.020 pp | USD11.66 -22.9% | 8 qtrs — |
| 67 | SQUAREPOINT OPS LLC | 142.7K +142.7K (+100.0%) | 1.28M +1.3M (+100.0%) | 0.13% +0.130 pp | 0.00% +0.001 pp | USD8.99 +0.0% | 1 qtrs NEW |
| 68 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 140.2K +2.3K (+1.7%) | 1.26M -1.1M (-47.1%) | 0.13% +0.002 pp | 0.00% -0.002 pp | USD28.59 -68.6% | 22 qtrs — |
| 69 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 132.6K +— (+0.0%) | 1.19M -1.1M (-47.9%) | 0.12% +0.000 pp | 0.02% -0.018 pp | USD8.98 +0.1% | 4 qtrs — |
| 70 | RHUMBLINE ADVISERS | 132.5K -27.0K (-16.9%) | 1.19M -1.6M (-56.8%) | 0.12% -0.025 pp | 0.00% -0.001 pp | USD29.90 -69.9% | 35 qtrs — |
| 71 | MILLENNIUM MANAGEMENT LLC | 126.4K -481.1K (-79.2%) | 1.14M -9.4M (-89.2%) | 0.11% -0.437 pp | 0.00% -0.004 pp | USD13.68 -34.3% | 29 qtrs — |
| 72 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 124.5K +4.1K (+3.4%) | 1.12M -956.2K (-46.1%) | 0.11% +0.004 pp | 0.00% -0.002 pp | USD21.30 -57.8% | 7 qtrs — |
| 73 | PRICE T ROWE ASSOCIATES INC /MD/ | 122.0K +29.5K (+31.9%) | 1.10M -501.0K (-31.4%) | 0.11% +0.027 pp | 0.00% 0.000 pp | USD23.05 -61.0% | 23 qtrs — |
| 74 | PDT PARTNERS, LLC | 121.5K -35.3K (-22.5%) | 1.09M -1.6M (-59.7%) | 0.11% -0.032 pp | 0.07% -0.100 pp | USD10.93 -17.7% | 10 qtrs — |
| 75 | LPL FINANCIAL LLC | 120.3K +17.3K (+16.8%) | 1.08M -697.9K (-39.2%) | 0.11% +0.016 pp | 0.00% 0.000 pp | USD25.27 -64.4% | 24 qtrs — |
| 76 | EDGESTREAM PARTNERS, L.P. | 111.2K +111.2K (+100.0%) | 999.3K +999.3K (+100.0%) | 0.10% +0.101 pp | 0.03% +0.028 pp | USD8.99 +0.0% | 1 qtrs NEW |
| 77 | OPPENHEIMER & CO INC | 105.2K +808.0 (+0.8%) | 945.4K -856.8K (-47.5%) | 0.10% +0.001 pp | 0.01% -0.009 pp | USD9.74 -7.7% | 5 qtrs — |
| 78 | ALLIANCEBERNSTEIN L.P. | 103.1K +— (+0.0%) | 926.9K -853.7K (-47.9%) | 0.09% +0.000 pp | 0.00% 0.000 pp | USD56.89 -84.2% | 39 qtrs — |
| 79 | CANAL INSURANCE CO | 100.0K +100.0K (+100.0%) | 899.0K +899.0K (+100.0%) | 0.09% +0.091 pp | 0.22% +0.218 pp | USD8.99 +0.0% | 1 qtrs NEW |
| 80 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 98.6K -14.8K (-13.1%) | 892.8K -1.1M (-54.4%) | 0.09% -0.014 pp | 0.00% -0.002 pp | USD11.45 -21.5% | 4 qtrs — |
| 81 | PANAGORA ASSET MANAGEMENT INC | 99.3K -99.4K (-50.0%) | 892.7K -2.5M (-74.0%) | 0.09% -0.090 pp | 0.00% -0.011 pp | USD17.27 -47.9% | 2 qtrs — |
| 82 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 99.0K +9.4K (+10.5%) | 890.1K -657.8K (-42.5%) | 0.09% +0.009 pp | 0.00% -0.001 pp | USD35.59 -74.7% | 39 qtrs — |
| 83 | LAZARD ASSET MANAGEMENT LLC | 98.8K -15.9K (-13.8%) | 887.9K -1.1M (-55.1%) | 0.09% -0.014 pp | 0.00% -0.001 pp | USD33.36 -73.1% | 18 qtrs — |
| 84 | DISCOVERY VALUE FUND | 98.0K -130.7K (-57.2%) | 880.8K -3.1M (-77.7%) | 0.09% -0.119 pp | 2.35% -4.703 pp | USD146.92 -93.9% | 20 qtrs — |
| 85 | LEGAL & GENERAL GROUP PLC | 96.9K -10.1K (-9.4%) | 871.5K -976.4K (-52.8%) | 0.09% -0.009 pp | 0.00% 0.000 pp | USD49.59 -81.9% | 39 qtrs — |
| 86 | COMMONWEALTH EQUITY SERVICES, LLC | 93.8K +4.2K (+4.7%) | 843.4K -704.6K (-45.5%) | 0.09% +0.004 pp | 0.00% -0.001 pp | USD15.77 -43.0% | 8 qtrs — |
| 87 | ATOM INVESTORS LP | 92.5K +92.5K (+100.0%) | 831.9K +831.9K (+100.0%) | 0.08% +0.084 pp | 0.07% +0.066 pp | USD8.99 +0.0% | 1 qtrs NEW |
| 88 | GROUP ONE TRADING, L.P. | 90.7K -6.4K (-6.6%) | 815.3K -861.4K (-51.4%) | 0.08% -0.006 pp | 0.00% -0.002 pp | USD9.83 -8.5% | 15 qtrs — |
| 89 | FREESTONE GROVE PARTNERS LP | 88.4K +88.4K (+100.0%) | 794.8K +794.8K (+100.0%) | 0.08% +0.080 pp | 0.01% +0.006 pp | USD8.99 +0.0% | 1 qtrs NEW |
| 90 | MOUNT YALE INVESTMENT ADVISORS, LLC | 86.6K +86.6K (+100.0%) | 778.3K +778.3K (+100.0%) | 0.08% +0.079 pp | 0.04% +0.038 pp | USD8.99 +0.0% | 1 qtrs NEW |
| 91 | D.A. DAVIDSON & CO. | 84.0K +19.8K (+30.8%) | 755.2K -353.9K (-31.9%) | 0.08% +0.018 pp | 0.00% -0.003 pp | USD12.15 -26.0% | 7 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 119 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | ARK Genomic Revolution ETF ARKG | 2.61% | 34.14M | 0.75% |
| 2 | ARK Innovation ETF ARKK | 2.61% | 170.66M | 0.75% |
| 3 | Global X - Genomics & Biotechnology ETF GNOM | 1.41% | 1.23M | 0.50% |
| 4 | Global X - Genomics & Biotechnology UCITS ETF GNOM.L | 1.41% | 736.8K | 0.50% |
| 5 | Horizon Kinetics Medical ETF MEDX | 0.96% | 178.9K | 0.85% |
| 6 | Global X - S&P Biotech ETF CURE.AX | 0.76% | 272.4K | 0.45% |
| 7 | State Street SPDR S&P Biotech ETF XBI | 0.76% | 82.05M | 0.35% |
| 8 | Virtus Biotech Clinical Trials ETF BBC | 0.72% | 415.9K | 0.65% |
| 9 | iShares Genomics Immunology and Healthcare ETF IDNA | 0.66% | 1.30M | 0.47% |
| 10 | WisdomTree BioRevolution UCITS ETF - USD Acc WDNA.L | 0.54% | 120.5K | 0.45% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.56
Bullish
Ratio by volume
3.00
Bullish
Buys
14
Sells
9
Shares acquired
947.0K
Shares disposed
85.7K
Cash buys
1.00
Cash sales
9.00
Net activity
+861,332
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-02 | Clark Eliana | Officer | S-Sale | D | Common Stock | 607 | 13.78 | 8.4K | 93,864 | D | ↗ |
| 2026-03-02 | BASTA JAMES | Officer | S-Sale | D | Common Stock | 1,211 | 13.78 | 16.7K | 156,794 | D | ↗ |
| 2026-03-01 | Schultes Birgit C | Officer | A-Award | A | Stock Option (right to buy) | 56,000 | 13.78 | 771.7K | 56,000 | D | ↗ |
| 2026-03-01 | Lebwohl David | Officer | A-Award | A | Stock Option (right to buy) | 14,204 | 13.78 | 195.7K | 14,204 | D | ↗ |
| 2026-03-01 | LEONARD JOHN M | Director / Officer | A-Award | A | Common Stock | 156,400 | 0.00 | — | 1,169,739 | D | ↗ |
| 2026-03-01 | Dulac Edward J III | Officer | A-Award | A | Stock Option (right to buy) | 87,543 | 13.78 | 1.21M | 87,543 | D | ↗ |
| 2026-03-01 | Dube Michael P | Officer | A-Award | A | Common Stock | 17,250 | 0.00 | — | 69,527 | D | ↗ |
| 2026-03-01 | Clark Eliana | Officer | A-Award | A | Stock Option (right to buy) | 10,505 | 13.78 | 144.8K | 10,505 | D | ↗ |
| 2026-03-01 | BASTA JAMES | Officer | A-Award | A | Stock Option (right to buy) | 65,829 | 13.78 | 907.1K | 65,829 | D | ↗ |
| 2026-01-05 | Schultes Birgit C | Officer | S-Sale | D | Common Stock | 8,508 | 9.21 | 78.4K | 98,533 | D | ↗ |
| 2026-01-05 | Lebwohl David | Officer | S-Sale | D | Common Stock | 11,903 | 9.21 | 109.6K | 121,249 | D | ↗ |
| 2026-01-05 | LEONARD JOHN M | Director / Officer | S-Sale | D | Common Stock | 34,146 | 9.21 | 314.5K | 1,013,339 | D | ↗ |
| 2026-01-05 | Dulac Edward J III | Officer | S-Sale | D | Common Stock | 6,379 | 9.21 | 58.8K | 99,683 | D | ↗ |
| 2026-01-05 | Dube Michael P | Officer | S-Sale | D | Common Stock | 2,989 | 9.21 | 27.5K | 52,277 | D | ↗ |
| 2026-01-05 | Cohen Fred E | Director | P-Purchase | A | Common Stock | 150,000 | 9.35 | 1.40M | 207,453 | D | ↗ |
| 2026-01-05 | Clark Eliana | Officer | S-Sale | D | Common Stock | 9,515 | 9.21 | 87.6K | 87,118 | D | ↗ |
| 2026-01-05 | BASTA JAMES | Officer | S-Sale | D | Common Stock | 10,397 | 9.21 | 95.8K | 101,528 | D | ↗ |
| 2025-12-12 | LEONARD JOHN M | Director / Officer | M-Exempt | A | Common Stock | 8,557 | 6.83 | 58.4K | 1,047,485 | D | ↗ |
| 2025-12-11 | LEONARD JOHN M | Director / Officer | S-Sale | D | Common Stock | 49,959 | 9.49 | 474.1K | 1,077,115 | D | ↗ |
| 2025-10-01 | Schultes Birgit C | Officer | S-Sale | D | Common Stock | 31 | 17.38 | 538.78 | 105,184 | D | ↗ |
| 2025-10-01 | Dube Michael P | Officer | S-Sale | D | Common Stock | 1,871 | 17.38 | 32.5K | 55,266 | D | ↗ |
| 2025-08-20 | CHASE WILLIAM J | Director | P-Purchase | A | Common Stock | 100,000 | 10.03 | 1.00M | 134,693 | D | ↗ |
| 2025-07-23 | Dulac Edward J III | Officer | S-Sale | D | Common Stock | 7,462 | 14.02 | 104.6K | 106,062 | D | ↗ |
| 2025-07-02 | Dube Michael P | Officer | S-Sale | D | Common Stock | 2,503 | 9.95 | 24.9K | 57,137 | D | ↗ |
| 2025-07-01 | GOODMAN JESSE | Director | S-Sale | D | Common Stock | 1,547 | 9.23 | 14.3K | 24,359 | D | ↗ |
| 2025-07-01 | Clark Eliana | Officer | S-Sale | D | Common Stock | 1,022 | 9.82 | 10.0K | 95,369 | D | ↗ |
| 2025-06-30 | GOODMAN JESSE | Director | S-Sale | D | Common Stock | 1,547 | 9.56 | 14.8K | 25,906 | D | ↗ |
| 2025-06-11 | Verwiel Frank | Director | A-Award | A | Stock Option (right to buy) | 11,450 | 8.37 | 95.8K | 11,450 | D | ↗ |
| 2025-06-11 | Keresty Georgia | Director | A-Award | A | Stock Option (right to buy) | 11,450 | 8.37 | 95.8K | 11,450 | D | ↗ |
| 2025-06-11 | Goff Brian | Director | A-Award | A | Stock Option (right to buy) | 11,450 | 8.37 | 95.8K | 11,450 | D | ↗ |
| 2025-06-11 | GOODMAN JESSE | Director | A-Award | A | Common Stock | 8,000 | 0.00 | — | 27,453 | D | ↗ |
| 2025-06-11 | Cohen Fred E | Director | A-Award | A | Common Stock | 8,000 | 0.00 | — | 57,453 | D | ↗ |
| 2025-06-11 | CHASE WILLIAM J | Director | A-Award | A | Stock Option (right to buy) | 11,450 | 8.37 | 95.8K | 11,450 | D | ↗ |
| 2025-06-11 | Bhanji Muna | Director | A-Award | A | Stock Option (right to buy) | 11,450 | 8.37 | 95.8K | 11,450 | D | ↗ |
| 2025-04-29 | Bhanji Muna | Director | S-Sale | D | Common Stock | 265 | 8.50 | 2.3K | 19,203 | D | ↗ |
| 2025-03-04 | Clark Eliana | Officer | S-Sale | D | Common Stock | 679 | 8.99 | 6.1K | 95,369 | D | ↗ |
| 2025-03-04 | BASTA JAMES | Officer | S-Sale | D | Common Stock | 2,572 | 8.99 | 23.1K | 111,925 | D | ↗ |
| 2025-03-01 | Schultes Birgit C | Officer | A-Award | A | Stock Option (right to buy) | 53,714 | 10.09 | 542.0K | 53,714 | D | ↗ |
| 2025-03-01 | Lebwohl David | Officer | A-Award | A | Common Stock | 43,200 | 0.00 | — | 130,866 | D | ↗ |
| 2025-03-01 | LEONARD JOHN M | Director / Officer | A-Award | A | Stock Option (right to buy) | 196,000 | 10.09 | 1.98M | 196,000 | D | ↗ |
| 2025-03-01 | Dulac Edward J III | Officer | A-Award | A | Common Stock | 47,200 | 0.00 | — | 113,524 | D | ↗ |
| 2025-03-01 | Dube Michael P | Officer | A-Award | A | Common Stock | 14,000 | 0.00 | — | 59,640 | D | ↗ |
| 2025-03-01 | Clark Eliana | Officer | A-Award | A | Common Stock | 32,000 | 0.00 | — | 96,048 | D | ↗ |
| 2025-03-01 | BASTA JAMES | Officer | A-Award | A | Stock Option (right to buy) | 57,143 | 10.09 | 576.6K | 57,143 | D | ↗ |
| 2025-01-29 | Bhanji Muna | Director | S-Sale | D | Common Stock | 265 | 9.97 | 2.6K | 19,468 | D | ↗ |
| 2025-01-13 | Schultes Birgit C | Officer | — | — | Stock Option (right to buy) | 10,625 | 14.58 | 154.9K | 0 | D | ↗ |
| 2025-01-03 | Sepp-Lorenzino Laura | Officer | S-Sale | D | Common Stock | 8,966 | 12.18 | 109.2K | 77,388 | D | ↗ |
| 2025-01-03 | Lebwohl David | Officer | S-Sale | D | Common Stock | 9,557 | 12.18 | 116.4K | 87,666 | D | ↗ |
| 2025-01-03 | LEONARD JOHN M | Director / Officer | S-Sale | D | Common Stock | 26,807 | 12.18 | 326.5K | 941,115 | D | ↗ |
| 2025-01-03 | Hicks Derek | Officer | S-Sale | D | Common Stock | 6,502 | 12.18 | 79.2K | 59,878 | D | ↗ |
| 2025-01-03 | Dube Michael P | Officer | S-Sale | D | Common Stock | 1,372 | 12.18 | 16.7K | 45,640 | D | ↗ |
| 2025-01-03 | Clark Eliana | Officer | S-Sale | D | Common Stock | 7,422 | 12.18 | 90.4K | 64,048 | D | ↗ |
| 2025-01-03 | BASTA JAMES | Officer | S-Sale | D | Common Stock | 7,074 | 12.18 | 86.2K | 74,497 | D | ↗ |
| 2025-01-02 | Clark Eliana | Officer | S-Sale | D | Common Stock | 556 | 12.03 | 6.7K | 71,470 | D | ↗ |
| 2025-01-01 | Sepp-Lorenzino Laura | Officer | M-Exempt | A | Common Stock | 3,500 | 0.00 | — | 86,354 | D | ↗ |
| 2025-01-01 | Lebwohl David | Officer | M-Exempt | A | Common Stock | 3,189 | 0.00 | — | 97,223 | D | ↗ |
| 2025-01-01 | LEONARD JOHN M | Director / Officer | M-Exempt | A | Common Stock | 7,850 | 0.00 | — | 967,922 | D | ↗ |
| 2024-10-02 | Dube Michael P | Officer | S-Sale | D | Common Stock | 2,012 | 19.01 | 38.2K | 47,012 | D | ↗ |
| 2024-07-22 | Dulac Edward J III | Officer | A-Award | A | Common Stock | 66,324 | 0.00 | — | 66,324 | — | ↗ |
| 2024-07-01 | Dube Michael P | Officer | A-Award | A | Common Stock | 17,801 | 0.00 | — | 49,024 | — | ↗ |
| 2024-07-01 | Clark Eliana | Officer | S-Sale | D | Common Stock | 405 | 22.93 | 9.3K | 71,470 | — | ↗ |
| 2024-06-17 | Verwiel Frank | Director | S-Sale | D | Common Stock | 1,505 | 25.00 | 37.6K | 17,948 | — | ↗ |
| 2024-06-13 | Goff Brian | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-06-12 | Verwiel Frank | Director | A-Award | A | Stock Option (right to buy) | 11,515 | 25.85 | 297.7K | 11,515 | — | ↗ |
| 2024-06-12 | Keresty Georgia | Director | A-Award | A | Stock Option (right to buy) | 11,515 | 25.85 | 297.7K | 11,515 | — | ↗ |
| 2024-06-12 | GOODMAN JESSE | Director | A-Award | A | Common Stock | 7,737 | 0.00 | — | 19,453 | — | ↗ |
| 2024-06-12 | Cohen Fred E | Director | A-Award | A | Common Stock | 7,737 | 0.00 | — | 49,453 | — | ↗ |
| 2024-06-12 | CHASE WILLIAM J | Director | A-Award | A | Common Stock | 7,737 | 0.00 | — | 26,693 | — | ↗ |
| 2024-06-12 | Bhanji Muna | Director | A-Award | A | Stock Option (right to buy) | 11,515 | 25.85 | 297.7K | 11,515 | — | ↗ |
| 2024-04-10 | Dube Michael P | Officer | — | D | Common Stock | 0 | 0.00 | — | 31,223 | — | ↗ |
| 2024-03-04 | Clark Eliana | Officer | S-Sale | D | Common Stock | 605 | 32.99 | 20.0K | 71,470 | — | ↗ |
| 2024-03-04 | BASTA JAMES | Officer | S-Sale | D | Common Stock | 2,297 | 32.99 | 75.8K | 81,571 | — | ↗ |
| 2024-03-01 | Sepp-Lorenzino Laura | Officer | A-Award | A | Stock Option (right to buy) | 54,794 | 32.66 | 1.79M | 54,794 | — | ↗ |
| 2024-03-01 | Lebwohl David | Officer | A-Award | A | Stock Option (right to buy) | 55,855 | 32.66 | 1.82M | 55,855 | — | ↗ |
| 2024-03-01 | LEONARD JOHN M | Director / Officer | A-Award | A | Stock Option (right to buy) | 163,929 | 32.66 | 5.35M | 163,929 | — | ↗ |
| 2024-03-01 | Hicks Derek | Officer | A-Award | A | Stock Option (right to buy) | 42,421 | 32.66 | 1.39M | 42,421 | — | ↗ |
| 2024-03-01 | Goddard Glenn | Officer | A-Award | A | Stock Option (right to buy) | 41,316 | 32.66 | 1.35M | 41,316 | — | ↗ |
| 2024-03-01 | Clark Eliana | Officer | A-Award | A | Stock Option (right to buy) | 45,072 | 32.66 | 1.47M | 45,072 | — | ↗ |
| 2024-03-01 | BASTA JAMES | Officer | A-Award | A | Stock Option (right to buy) | 46,752 | 32.66 | 1.53M | 46,752 | — | ↗ |
| 2024-01-08 | Sepp-Lorenzino Laura | Officer | S-Sale | D | Common Stock | 1,608 | 28.66 | 46.1K | 44,594 | — | ↗ |
| 2024-01-03 | Sepp-Lorenzino Laura | Officer | S-Sale | D | Common Stock | 5,532 | 29.46 | 163.0K | 46,202 | — | ↗ |
| 2024-01-03 | Lebwohl David | Officer | S-Sale | D | Common Stock | 5,843 | 29.46 | 172.1K | 54,372 | — | ↗ |
| 2024-01-03 | LEONARD JOHN M | Director / Officer | S-Sale | D | Common Stock | 19,223 | 29.46 | 566.3K | 846,486 | — | ↗ |
| 2024-01-03 | Hicks Derek | Officer | S-Sale | D | Common Stock | 3,877 | 29.46 | 114.2K | 36,987 | — | ↗ |
| 2024-01-03 | Goddard Glenn | Officer | S-Sale | D | Common Stock | 5,365 | 29.46 | 158.1K | 40,585 | — | ↗ |
| 2024-01-03 | Clark Eliana | Officer | S-Sale | D | Common Stock | 4,301 | 29.46 | 126.7K | 40,845 | — | ↗ |
| 2024-01-03 | BASTA JAMES | Officer | S-Sale | D | Common Stock | 3,805 | 29.46 | 112.1K | 51,474 | — | ↗ |
| 2024-01-01 | Sepp-Lorenzino Laura | Officer | M-Exempt | A | Common Stock | 3,500 | 0.00 | — | 51,734 | — | ↗ |
| 2024-01-01 | Lebwohl David | Officer | M-Exempt | A | Common Stock | 3,187 | 0.00 | — | 60,215 | — | ↗ |
| 2024-01-01 | LEONARD JOHN M | Director / Officer | M-Exempt | A | Common Stock | 7,848 | 0.00 | — | 865,709 | — | ↗ |
| 2024-01-01 | Goddard Glenn | Officer | M-Exempt | D | Restricted Stock Unit | 3,062 | 0.00 | — | 3,064 | — | ↗ |
| 2023-10-31 | Bhanji Muna | Director | S-Sale | D | Common Stock | 265 | 23.90 | 6.3K | 11,996 | — | ↗ |
| 2023-07-31 | Bhanji Muna | Director | S-Sale | D | Common Stock | 265 | 42.33 | 11.2K | 12,261 | — | ↗ |
| 2023-07-06 | Bhanji Muna | Director | S-Sale | D | Common Stock | 1,867 | 39.30 | 73.4K | 12,526 | — | ↗ |
| 2023-07-03 | Clark Eliana | Officer | S-Sale | D | Common Stock | 360 | 40.51 | 14.6K | 45,146 | — | ↗ |
| 2023-06-20 | Clark Eliana | Officer | M-Exempt | D | Stock Option (right to buy) | 5,000 | 12.27 | 61.4K | 57,750 | — | ↗ |
| 2023-06-14 | Verwiel Frank | Director | A-Award | A | Stock Option (right to buy) | 6,473 | 45.20 | 292.6K | 6,473 | — | ↗ |
| 2023-06-14 | Keresty Georgia | Director | A-Award | A | Stock Option (right to buy) | 6,473 | 45.20 | 292.6K | 6,473 | — | ↗ |
| 2023-06-14 | GOODMAN JESSE | Director | A-Award | A | Stock Option (right to buy) | 6,473 | 45.20 | 292.6K | 6,473 | — | ↗ |
| 2023-06-14 | Crowley John F | Director | A-Award | A | Stock Option (right to buy) | 6,473 | 45.20 | 292.6K | 6,473 | — | ↗ |
| 2023-06-14 | Cohen Fred E | Director | A-Award | A | Stock Option (right to buy) | 6,473 | 45.20 | 292.6K | 6,473 | — | ↗ |
| 2023-06-14 | CHASE WILLIAM J | Director | A-Award | A | Stock Option (right to buy) | 2,447 | 45.20 | 110.6K | 2,447 | — | ↗ |
| 2023-06-14 | Bhanji Muna | Director | A-Award | A | Stock Option (right to buy) | 6,473 | 45.20 | 292.6K | 6,473 | — | ↗ |
| 2023-04-14 | CHASE WILLIAM J | Director | — | D | Common Stock | 0 | 0.00 | — | 6,800 | — | ↗ |
| 2023-03-02 | BASTA JAMES | Officer | S-Sale | D | Common Stock | 1,088 | 43.88 | 47.7K | 55,279 | — | ↗ |
| 2023-03-01 | Sepp-Lorenzino Laura | Officer | A-Award | A | Common Stock | 29,938 | 0.00 | — | 47,567 | — | ↗ |
| 2023-03-01 | Lebwohl David | Officer | A-Award | A | Stock Option (right to buy) | 43,342 | 40.75 | 1.77M | 43,342 | — | ↗ |
| 2023-03-01 | LEONARD JOHN M | Director / Officer | A-Award | A | Common Stock | 91,036 | 0.00 | — | 857,861 | — | ↗ |
| 2023-03-01 | Hicks Derek | Officer | A-Award | A | Stock option (right to buy) | 33,287 | 40.75 | 1.36M | 33,287 | — | ↗ |
| 2023-03-01 | Goddard Glenn | Officer | A-Award | A | Stock Option (right to buy) | 38,834 | 40.75 | 1.58M | 38,834 | — | ↗ |
| 2023-03-01 | Clark Eliana | Officer | A-Award | A | Stock Option (right to buy) | 34,674 | 40.75 | 1.41M | 34,674 | — | ↗ |
| 2023-03-01 | BASTA JAMES | Officer | A-Award | A | Stock Option (right to buy) | 34,674 | 40.75 | 1.41M | 34,674 | — | ↗ |
| 2023-01-05 | Sepp-Lorenzino Laura | Officer | S-Sale | D | Common Stock | 1,641 | 38.22 | 62.7K | 18,318 | — | ↗ |
| 2023-01-04 | Sepp-Lorenzino Laura | Officer | S-Sale | D | Common Stock | 2,508 | 37.21 | 93.3K | 19,959 | — | ↗ |
| 2023-01-04 | Lebwohl David | Officer | S-Sale | D | Common Stock | 2,574 | 37.21 | 95.8K | 25,687 | — | ↗ |
| 2023-01-04 | LEONARD JOHN M | Officer | S-Sale | D | Common Stock | 6,673 | 37.21 | 248.3K | 766,825 | — | ↗ |
| 2023-01-04 | Hicks Derek | Officer | S-Sale | D | Common Stock | 1,812 | 37.21 | 67.4K | 17,306 | — | ↗ |
| 2023-01-04 | Goddard Glenn | Officer | S-Sale | D | Common Stock | 2,427 | 37.21 | 90.3K | 15,404 | — | ↗ |
| 2023-01-04 | Clark Eliana | Officer | S-Sale | D | Common Stock | 1,692 | 37.21 | 63.0K | 14,473 | — | ↗ |
| 2023-01-04 | BASTA JAMES | Officer | S-Sale | D | Common Stock | 1,138 | 37.21 | 42.3K | 19,559 | — | ↗ |
| 2023-01-03 | Clark Eliana | Officer | S-Sale | D | Common Stock | 231 | 34.48 | 8.0K | 16,165 | — | ↗ |
| 2023-01-01 | Sepp-Lorenzino Laura | Officer | M-Exempt | A | Common Stock | 3,500 | 0.00 | — | 22,467 | — | ↗ |
| 2023-01-01 | Lebwohl David | Officer | M-Exempt | A | Common Stock | 3,187 | 0.00 | — | 28,261 | — | ↗ |
| 2023-01-01 | LEONARD JOHN M | Officer | M-Exempt | A | Common Stock | 7,848 | 0.00 | — | 773,498 | — | ↗ |
| 2023-01-01 | Goddard Glenn | Officer | M-Exempt | A | Common Stock | 3,062 | 0.00 | — | 17,831 | — | ↗ |
| 2022-06-14 | Verwiel Frank | Director | A-Award | A | Common Stock | 5,197 | 0.00 | — | 7,291 | — | ↗ |
| 2022-06-14 | Keresty Georgia | Director | A-Award | A | Stock Option (right to buy) | 7,688 | 0.00 | — | 7,688 | — | ↗ |
| 2022-06-14 | GOODMAN JESSE | Director | A-Award | A | Common Stock | 5,197 | 0.00 | — | 7,291 | — | ↗ |
| 2022-06-14 | FORMELA JEAN FRANCOIS | Director | A-Award | A | Common Stock | 5,197 | 0.00 | — | 7,291 | — | ↗ |
| 2022-06-14 | DORSA CAROLINE | Director | A-Award | A | Stock Option (right to buy) | 7,688 | 0.00 | — | 7,688 | — | ↗ |
| 2022-06-14 | Crowley John F | Director | A-Award | A | Common Stock | 5,197 | 0.00 | — | 7,291 | — | ↗ |
| 2022-06-14 | Cohen Fred E | Director | A-Award | A | Stock Option (right to buy) | 7,688 | 38.49 | 295.9K | 7,688 | — | ↗ |
| 2022-06-14 | Bhanji Muna | Director | A-Award | A | Common Stock | 2,014 | 0.00 | — | 9,968 | — | ↗ |
| 2022-04-28 | Bhanji Muna | Director | A-Award | A | Stock Option (Right to Buy) | 11,700 | 0.00 | — | 11,700 | — | ↗ |
| 2022-03-01 | Sepp-Lorenzino Laura | Officer | A-Award | A | Stock Option (right to buy) | 13,816 | 79.85 | 1.10M | 13,816 | — | ↗ |
| 2022-03-01 | Lebwohl David | Officer | A-Award | A | Stock Option (right to buy) | 13,816 | 79.85 | 1.10M | 13,816 | — | ↗ |
| 2022-03-01 | LEONARD JOHN M | Director / Officer | A-Award | A | Stock Option (right to buy) | 59,941 | 79.85 | 4.79M | 59,941 | — | ↗ |
| 2022-03-01 | Goddard Glenn | Officer | A-Award | A | Stock Option (right to buy) | 12,720 | 79.85 | 1.02M | 12,720 | — | ↗ |
| 2022-03-01 | Clark Eliana | Officer | A-Award | A | Stock Option (right to buy) | 15,395 | 79.85 | 1.23M | 15,395 | — | ↗ |
| 2022-03-01 | BASTA JAMES | Officer | A-Award | A | Common Stock | 9,648 | 0.00 | — | 20,697 | — | ↗ |
| 2022-01-03 | Hicks Derek | Officer | A-Award | A | Stock option (right to buy) | 25,000 | 118.99 | 2.97M | 25,000 | — | ↗ |
| 2022-01-01 | Sepp-Lorenzino Laura | Officer | M-Exempt | A | Common Stock | 3,500 | 0.00 | — | 5,963 | — | ↗ |
| 2022-01-01 | Lebwohl David | Officer | M-Exempt | D | Restricted Stock Unit | 3,187 | 0.00 | — | 9,563 | — | ↗ |
| 2022-01-01 | LEONARD JOHN M | Director / Officer | M-Exempt | D | Restricted Stock Unit | 7,848 | 0.00 | — | 23,546 | — | ↗ |
| 2022-01-01 | Goddard Glenn | Officer | S-Sale | D | Common Stock | 1,013 | 112.24 | 113.7K | 2,049 | — | ↗ |
| 2021-12-20 | Hicks Derek | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-05 | Lebwohl David | Officer | S-Sale | D | Common Stock | 452 | 132.62 | 59.9K | 9,462 | — | ↗ |
| 2021-10-14 | Lebwohl David | Officer | S-Sale | D | Common Stock | 250 | 130.47 | 32.6K | 8,714 | — | ↗ |
| 2021-10-11 | Crowley John F | Director | M-Exempt | D | Stock Option (right to buy) | 2,500 | 18.83 | 47.1K | 25,500 | — | ↗ |
| 2021-10-05 | Crowley John F | Director | M-Exempt | D | Stock Option (right to buy) | 10,000 | 18.83 | 188.3K | 28,000 | — | ↗ |
| 2021-09-24 | Lebwohl David | Officer | M-Exempt | A | Common Stock | 7,923 | 12.62 | 100.0K | 8,714 | — | ↗ |
| 2021-09-21 | Lebwohl David | Officer | S-Sale | D | Common Stock | 2,400 | 149.81 | 359.5K | 791 | — | ↗ |
| 2021-09-07 | Goddard Glenn | Officer | S-Sale | D | Common Stock | 3,482 | 180.12 | 627.2K | 0 | — | ↗ |
| 2021-09-01 | LEONARD JOHN M | Director / Officer | S-Sale | D | Common Stock | 44,735 | 170.00 | 7.60M | 719,305 | — | ↗ |
| 2021-08-31 | LEONARD JOHN M | Director / Officer | S-Sale | D | Common Stock | 37,833 | 155.00 | 5.86M | 719,305 | — | ↗ |
| 2021-08-31 | Goddard Glenn | Officer | M-Exempt | D | Stock Option (right to buy) | 1,817 | 14.58 | 26.5K | 15,933 | — | ↗ |
| 2021-08-30 | Sepp-Lorenzino Laura | Officer | S-Sale | D | Common Stock | 2,653 | 159.64 | 423.5K | 2,598 | — | ↗ |
| 2021-08-30 | Lebwohl David | Officer | S-Sale | D | Common Stock | 150 | 160.10 | 24.0K | 791 | — | ↗ |
| 2021-08-30 | LEONARD JOHN M | Director / Officer | M-Exempt | A | Common Stock | 11,637 | 13.40 | 155.9K | 730,942 | — | ↗ |
| 2021-08-30 | Goddard Glenn | Officer | S-Sale | D | Common Stock | 704 | 153.22 | 107.9K | 4,496 | — | ↗ |
| 2021-08-23 | LEONARD JOHN M | Director / Officer | S-Sale | D | Common Stock | 18,874 | 151.54 | 2.86M | 727,570 | — | ↗ |
| 2021-08-19 | LEONARD JOHN M | Director / Officer | M-Exempt | A | Common Stock | 22,682 | 13.40 | 303.9K | 741,987 | — | ↗ |
| 2021-08-09 | Lebwohl David | Officer | S-Sale | D | Common Stock | 2,400 | 164.05 | 393.7K | 791 | — | ↗ |
| 2021-08-05 | Goddard Glenn | Officer | M-Exempt | D | Stock Option (right to buy) | 20,000 | 19.27 | 385.4K | 70,000 | — | ↗ |
| 2021-08-04 | Sepp-Lorenzino Laura | Officer | M-Exempt | D | Stock Option (right to buy) | 26,000 | 13.40 | 348.4K | 109,000 | — | ↗ |
| 2021-07-01 | BASTA JAMES | Officer | A-Award | A | Stock Option (Right to Buy) | 130,000 | 171.65 | 22.31M | 130,000 | — | ↗ |
| 2021-06-28 | FORMELA JEAN FRANCOIS | Director | S-Sale | D | Common Stock | 21,893 | 135.83 | 2.97M | 111,106 | — | ↗ |
| 2021-06-23 | Verwiel Frank | Director | A-Award | A | Stock Option (right to buy) | 3,382 | 83.59 | 282.7K | 3,382 | — | ↗ |
| 2021-06-23 | Keresty Georgia | Director | A-Award | A | Common Stock | 2,094 | 0.00 | — | 2,094 | — | ↗ |
| 2021-06-23 | GOODMAN JESSE | Director | A-Award | A | Common Stock | 2,094 | 0.00 | — | 2,094 | — | ↗ |
| 2021-06-23 | FORMELA JEAN FRANCOIS | Director | A-Award | A | Stock Option (right to buy) | 3,382 | 83.59 | 282.7K | 3,382 | — | ↗ |
| 2021-06-23 | DORSA CAROLINE | Director | A-Award | A | Common Stock | 2,094 | 0.00 | — | 2,094 | — | ↗ |
| 2021-06-23 | Crowley John F | Director | A-Award | A | Common Stock | 2,094 | 0.00 | — | 2,094 | — | ↗ |
| 2021-06-23 | Cohen Fred E | Director | A-Award | A | Stock Option (right to buy) | 3,382 | 83.59 | 282.7K | 3,382 | — | ↗ |
| 2021-06-23 | BASTA JAMES | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-14 | FORMELA JEAN FRANCOIS | Director | S-Sale | D | Common Stock | 16,293 | 85.92 | 1.40M | 717,862 | — | ↗ |
| 2021-06-11 | FORMELA JEAN FRANCOIS | Director | S-Sale | D | Common Stock | 29,071 | 85.18 | 2.48M | 736,030 | — | ↗ |
| 2021-04-29 | FORMELA JEAN FRANCOIS | Director | S-Sale | D | Common Stock | 4,513 | 85.43 | 385.5K | 765,101 | — | ↗ |
| 2021-04-28 | FORMELA JEAN FRANCOIS | Director | S-Sale | D | Common Stock | 102,186 | 85.40 | 8.73M | 799,354 | — | ↗ |
| 2021-04-27 | FORMELA JEAN FRANCOIS | Director | S-Sale | D | Common Stock | 79,714 | 85.39 | 6.81M | 1,032,056 | — | ↗ |
| 2021-04-26 | FORMELA JEAN FRANCOIS | Director | S-Sale | D | Common Stock | 806 | 84.93 | 68.5K | 1,111,770 | — | ↗ |
| 2021-04-13 | LEONARD JOHN M | Director / Officer | M-Exempt | A | Common Stock | 10,000 | 6.83 | 68.3K | 703,368 | — | ↗ |
| 2021-04-09 | Keresty Georgia | Director | A-Award | A | Common Stock | 4,955 | 0.00 | — | 4,955 | — | ↗ |
| 2021-04-05 | FORMELA JEAN FRANCOIS | Director | S-Sale | D | Common Stock | 800 | 84.98 | 68.0K | 1,112,576 | — | ↗ |
| 2021-04-05 | DORSA CAROLINE | Director | M-Exempt | A | Common Stock | 7,500 | 6.40 | 48.0K | 12,910 | — | ↗ |
| 2021-04-01 | Rivera Jose E | Officer | M-Exempt | D | Stock Option (right to buy) | 33,000 | 13.88 | 458.0K | 39,000 | — | ↗ |
| 2021-04-01 | LEONARD JOHN M | Officer | M-Exempt | D | Stock Option (right to buy) | 45,000 | 14.58 | 656.1K | 155,000 | — | ↗ |
| 2021-03-03 | Sepp-Lorenzino Laura | Officer | A-Award | A | Restricted Stock Unit | 14,000 | 0.00 | — | 14,000 | — | ↗ |
| 2021-03-03 | SCHIERMEIER ANDREW | Officer | A-Award | A | Restricted Stock Unit | 13,125 | 0.00 | — | 13,125 | — | ↗ |
| 2021-03-03 | Rivera Jose E | Officer | A-Award | A | Restricted Stock Unit | 12,250 | 0.00 | — | 12,250 | — | ↗ |
| 2021-03-03 | Lebwohl David | Officer | A-Award | A | Restricted Stock Unit | 12,750 | 0.00 | — | 12,750 | — | ↗ |
| 2021-03-03 | LEONARD JOHN M | Director / Officer | A-Award | A | Stock Option (right to buy) | 188,363 | 57.71 | 10.87M | 188,363 | — | ↗ |
| 2021-03-03 | Goddard Glenn | Officer | A-Award | A | Stock Option (right to buy) | 73,500 | 57.71 | 4.24M | 73,500 | — | ↗ |
| 2021-02-26 | FORMELA JEAN FRANCOIS | Director | S-Sale | D | Common Stock | 501,945 | 60.29 | 30.26M | 1,113,376 | — | ↗ |
| 2021-02-09 | Rivera Jose E | Officer | M-Exempt | A | Common Stock | 21,000 | 18.30 | 384.2K | 129,409 | — | ↗ |
| 2021-02-09 | LEONARD JOHN M | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 56,718 | 6.83 | 387.4K | 68,516 | — | ↗ |
| 2021-02-05 | LEONARD JOHN M | Director / Officer | S-Sale | D | Common Stock | 14,018 | 67.86 | 951.3K | 632,742 | — | ↗ |
| 2021-02-03 | LEONARD JOHN M | Officer | M-Exempt | D | Stock Option (right to buy) | 50,000 | 22.78 | 1.14M | 110,000 | — | ↗ |
| 2021-02-01 | Rivera Jose E | Officer | S-Sale | D | Common Stock | 10,476 | 63.31 | 663.2K | 109,592 | — | ↗ |
| 2021-02-01 | LEONARD JOHN M | Officer | M-Exempt | D | Stock Option (right to buy) | 30,000 | 18.30 | 548.9K | 27,500 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-10.2K
Shares Outstanding
118.13M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | John M. Leonard, M.D. President, Chief Executive Officer | 708.0K | 529.2K | 2.44M | 1.36M | — | 26.4K | 5.06M | 75.05% | ↗ |
| 2 | 2025 | Edward J. Dulac III Executive Vice President, Chief Financial Officer and Treasurer | 526.0K | 271.0K | 848.2K | 466.6K | — | 56.7K | 2.17M | 60.63% | ↗ |
| 3 | 2025 | David Lebwohl, M.D. Executive Vice President, Chief Medical Officer | 536.0K | 234.2K | 776.3K | 427.1K | — | 11.1K | 1.98M | 60.63% | ↗ |
| 4 | 2025 | James Basta, J.D. Executive Vice President, General Counsel and Corporate Secretary | 494.0K | 227.2K | 718.8K | 395.4K | — | 11.1K | 1.85M | 60.34% | ↗ |
| 5 | 2025 | Birgit Schultes, Ph.D. Executive Vice President, Chief Scientific Officer | 475.0K | 207.6K | 675.7K | 371.7K | — | 10.1K | 1.74M | 60.19% | ↗ |
| 6 | 2024 | John M. Leonard, M.D. President, Chief Executive Officer | 687.0K | 424.2K | 10.49M | 3.71M | — | 24.5K | 15.33M | 92.59% | ↗ |
| 7 | 2024 | Edward J. Dulac III Executive Vice President, Chief Financial Officer and Treasurer | 228.2K | 303.5K | 4.46M | 1.68M | — | 24.0K | 6.69M | 91.70% | ↗ |
| 8 | 2024 | David Lebwohl, M.D. Executive Vice President, Chief Medical Officer | 520.0K | 201.6K | 3.58M | 1.26M | — | 11.1K | 5.58M | 86.86% | ↗ |
| 9 | 2024 | Laura Sepp-Lorenzino, Ph.D. Executive Vice President, Chief Scientific Officer | 512.0K | 184.8K | 3.53M | 1.24M | — | 35.9K | 5.51M | 86.69% | ↗ |
| 10 | 2024 | James Basta, J.D. Executive Vice President, General Counsel and Corporate Secretary | 479.0K | 166.2K | 3.16M | 1.06M | — | 11.1K | 4.87M | 86.53% | ↗ |
| 11 | 2024 | Glenn G. Goddard Former Executive Vice President, Chief Financial Officer and Treasurer | 243.5K | — | 2.87M | 934.3K | — | 395.9K | 4.45M | 85.62% | ↗ |
| 12 | 2024 | Michael P. Dube Vice President, Chief Accounting Officer, Former Interim Principal Financial | 364.0K | 103.7K | 864.4K | — | — | 10.7K | 1.34M | 64.37% | ↗ |
| 13 | 2023 | John M. Leonard, M.D. President, Chief Executive Officer | 660.0K | 429.0K | 6.83M | 3.71M | — | 31.2K | 11.66M | 90.39% | ↗ |
| 14 | 2023 | David Lebwohl, M.D. Executive Vice President, Chief Medical Officer | 495.0K | 202.0K | 2.30M | 1.25M | — | 10.6K | 4.26M | 83.38% | ↗ |
| 15 | 2023 | Laura Sepp-Lorenzino, Ph.D. Executive Vice President, Chief Scientific Officer | 492.0K | 196.8K | 2.25M | 1.22M | — | 32.1K | 4.19M | 82.78% | ↗ |
| 16 | 2023 | James Basta, J.D. Executive Vice President, General Counsel and Corporate Secretary | 460.0K | 184.0K | 2.34M | 999.3K | — | 10.5K | 3.99M | 83.61% | ↗ |
| 17 | 2023 | Glenn G. Goddard Former Executive Vice President, Chief Financial Officer and Treasurer | 468.0K | 159.1K | 2.06M | 1.12M | — | 10.5K | 3.82M | 83.30% | ↗ |
| 18 | 2023 | Glenn G. Goddard Executive Vice President, Chief Financial Officer and Treasurer | 468.0K | 159.1K | 2.06M | 1.12M | — | 10.5K | 3.82M | 83.30% | ↗ |
| 19 | 2022 | John M. Leonard, M.D. President, Chief Executive Officer | 630.0K | 401.3K | 5.87M | 3.17M | — | 29.5K | 10.10M | 89.49% | ↗ |
| 20 | 2022 | Derek Hicks Executive Vice President, Chief Business Officer | 420.0K | 370.0K | 2.27M | 1.98M | — | 33.5K | 5.08M | 83.80% | ↗ |
| 21 | 2022 | David Lebwohl, M.D. Executive Vice President, Chief Medical Officer | 475.3K | 186.3K | 1.98M | 1.07M | — | 9.8K | 3.72M | 81.94% | ↗ |
| 22 | 2022 | Laura Sepp-Lorenzino, Ph.D. Executive Vice President, Chief Scientific Officer | 470.0K | 189.8K | 1.98M | 1.07M | — | 10.8K | 3.72M | 81.95% | ↗ |
| 23 | 2022 | James Basta, J.D. Executive Vice President, General Counsel and Corporate Secretary | 435.6K | 170.8K | 2.26M | 746.2K | — | 9.8K | 3.63M | 83.00% | ↗ |
| 24 | 2022 | Glenn G. Goddard Former Executive Vice President, Chief Financial Officer and Treasurer | 450.0K | 171.1K | 1.82M | 983.8K | — | 9.8K | 3.43M | 81.63% | ↗ |
| 25 | 2022 | Glenn G. Goddard Executive Vice President, Chief Financial Officer and Treasurer | 450.0K | 171.1K | 1.82M | 983.8K | — | 9.8K | 3.43M | 81.63% | ↗ |
| 26 | 2021 | James Basta, J.D. Executive Vice President, General Counsel and Corporate Secretary | 219.7K | 235.2K | — | 14.61M | — | 5.4K | 15.07M | 96.95% | ↗ |
| 27 | 2021 | John M. Leonard, M.D. President, Chief Executive Officer | 600.0K | 462.0K | 1.81M | 6.88M | — | 22.9K | 9.77M | 88.90% | ↗ |
| 28 | 2021 | Laura Sepp-Lorenzino, Ph.D. Executive Vice President, Chief Scientific Officer | 441.0K | 259.3K | 807.9K | 3.07M | — | 4.8K | 4.58M | 84.60% | ↗ |
| 29 | 2021 | David Lebwohl, M.D. Executive Vice President, Chief Medical Officer | 458.3K | 269.5K | 735.8K | 2.79M | — | 9.1K | 4.27M | 82.73% | ↗ |
| 30 | 2021 | Glenn G. Goddard Executive Vice President, Chief Financial Officer and Treasurer | 419.2K | 234.8K | 706.9K | 2.68M | — | 9.1K | 4.05M | 83.64% | ↗ |
| 31 | 2020 | John M. Leonard, M.D. President, Chief Executive Officer | 580.0K | 319.0K | — | 2.72M | — | 13.8K | 3.64M | 74.89% | ↗ |
| 32 | 2020 | David Lebwohl, M.D. Executive Vice President, Chief Medical Officer | 298.4K | 228.0K | — | 1.55M | — | 2.7K | 2.08M | 74.55% | ↗ |
| 33 | 2020 | Andrew D. Schiermeier, Ph.D. Executive Vice President, Chief Operating Officer | 455.4K | 173.1K | — | 1.08M | — | 8.9K | 1.72M | 62.91% | ↗ |
| 34 | 2020 | Laura Sepp-Lorenzino, Ph.D. Executive Vice President, Chief Scientific Officer | 420.0K | 184.8K | — | 1.08M | — | 4.6K | 1.69M | 63.95% | ↗ |
| 35 | 2020 | Glenn G. Goddard Executive Vice President, Chief Financial Officer and Treasurer | 407.0K | 146.5K | — | 1.00M | — | 8.9K | 1.56M | 64.03% | ↗ |
| 36 | 2019 | Laura Sepp-Lorenzino, Ph.D. Executive Vice President, Chief Scientific Officer | 239.5K | 204.1K | — | 1.32M | — | 221.00 | 1.76M | 74.82% | ↗ |
| 37 | 2019 | Andrew D. Schiermeier, Ph.D. Executive Vice President, Chief Operating Officer | 440.0K | 167.2K | — | 611.9K | — | 8.8K | 1.23M | 49.83% | ↗ |
| 38 | 2019 | John M. Leonard, M.D. President, Chief Executive Officer | 559.2K | 307.6K | — | — | — | 37.0K | 903.8K | 0.00% | ↗ |
| 39 | 2019 | José E. Rivera, J.D. Executive Vice President, General Counsel | 423.8K | 169.5K | — | — | — | 44.3K | 637.6K | 0.00% | ↗ |
| 40 | 2019 | Glenn G. Goddard Executive Vice President, Chief Financial Officer | 383.0K | 153.2K | — | — | — | 5.6K | 541.8K | 0.00% | ↗ |
| 41 | 2019 | Glenn G. Goddard Executive Vice President, Chief Financial Officer and Treasurer | 383.0K | 153.2K | — | — | — | 5.6K | 541.8K | 0.00% | ↗ |
| 42 | 2018 | John M. Leonard, M.D. President, Chief Executive Officer | 550.0K | 302.5K | 1.01M | 7.82M | — | 26.1K | 9.71M | 90.95% | ↗ |
| 43 | 2018 | Andrew D. Schiermeier, Ph.D. Executive Vice President, Chief Operating Officer | 408.9K | 182.6K | 295.6K | 2.03M | — | 9.7K | 2.93M | 79.45% | ↗ |
| 44 | 2018 | Andrew D. Schiermeier, Ph.D. Executive Vice President, Development and Corporate Strategy | 408.9K | 182.6K | 295.6K | 2.03M | — | 9.7K | 2.93M | 79.45% | ↗ |
| 45 | 2018 | José E. Rivera, J.D. Executive Vice President, General Counsel | 417.2K | 166.9K | 337.2K | 1.69M | — | 37.2K | 2.65M | 76.53% | ↗ |
| 46 | 2018 | Glenn G. Goddard Executive Vice President, Chief Financial Officer | 67.7K | 51.7K | — | 1.90M | — | 218.00 | 2.02M | 94.07% | ↗ |
| 47 | 2018 | Glenn G. Goddard Executive Vice President, Chief Financial Officer and Treasurer | 67.7K | 51.7K | — | 1.90M | — | 218.00 | 2.02M | 94.07% | ↗ |
| 48 | 2018 | Graeme Bell Former Executive Vice President, Chief Financial Officer | 265.4K | — | 337.2K | 934.2K | — | 25.9K | 1.56M | 81.36% | ↗ |
| 49 | 2017 | Nessan Bermingham, Ph.D. Former President and Chief Executive Officer | 524.8K | 324.0K | — | 9.90M | — | 529.5K | 11.27M | 87.77% | ↗ |
| 50 | 2017 | Graeme Bell Former Executive Vice President, Chief Financial Officer | 400.0K | 178.5K | — | 3.17M | — | 49.0K | 3.80M | 83.48% | ↗ |
| 51 | 2017 | Graeme Bell Executive Vice President, Chief Financial Officer | 400.0K | 178.5K | — | 3.17M | — | 49.0K | 3.80M | 83.48% | ↗ |
| 52 | 2017 | José E. Rivera, J.D. Executive Vice President, General Counsel | 403.8K | 180.7K | — | 2.23M | — | 34.0K | 2.85M | 78.32% | ↗ |
| 53 | 2017 | John M. Leonard, M.D. President, Chief Executive Officer | 395.8K | 156.2K | — | 2.02M | — | 16.6K | 2.59M | 78.07% | ↗ |
| 54 | 2017 | John M. Leonard, M.D. President and Chief Executive Officer (former Executive Vice President, Research & Development) | 395.8K | 156.2K | — | 2.02M | — | 16.6K | 2.59M | 78.07% | ↗ |
| 55 | 2016 | Nessan Bermingham, Ph.D. Former President and Chief Executive Officer | 450.0K | 225.0K | — | 3.34M | — | 718.00 | 4.01M | 83.17% | ↗ |
| 56 | 2016 | Nessan Bermingham, Ph.D. President and Chief Executive Officer | 450.0K | 225.0K | — | 3.34M | — | 718.00 | 4.01M | 83.17% | ↗ |
| 57 | 2016 | John M. Leonard, M.D. Executive Vice President, Research & Development | 300.0K | 123.8K | — | 1.74M | — | 41.0K | 2.21M | 78.94% | ↗ |
| 58 | 2016 | John M. Leonard, M.D. President, Chief Executive Officer | 300.0K | 123.8K | — | 1.74M | — | 41.0K | 2.21M | 78.94% | ↗ |
| 59 | 2016 | John M. Leonard, M.D. President and Chief Executive Officer (former Executive Vice President, Research & Development) | 300.0K | 123.8K | — | 1.74M | — | 41.0K | 2.21M | 78.94% | ↗ |
| 60 | 2016 | José E. Rivera, J.D. Executive Vice President, General Counsel | 375.0K | 154.7K | — | 871.1K | — | 34.7K | 1.44M | 60.68% | ↗ |
| 61 | 2015 | Nessan Bermingham, Ph.D. President and Chief Executive Officer | 383.3K | 180.0K | — | — | — | — | 563.3K | 0.00% | ↗ |
| 62 | 2015 | José E. Rivera, J.D. Executive Vice President, General Counsel | 325.0K | 123.8K | — | — | — | 47.4K | 496.2K | 0.00% | ↗ |
| 63 | 2015 | John M. Leonard, M.D. Executive Vice President, Research & Development | 300.0K | 99.0K | — | — | — | 51.4K | 450.4K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jennifer A. Doudna | Founder and Member of Scientific Advisor Board | 1M | — |
| Derrick J. Rossi | Founder and Member of Scientific Advisor Board | 1M | — |
| Rodolphe Barrangou | Founder and Member of Scientific Advisor Board | 1M | — |
| Erik J. Sontheimer | Founder and Member of Scientific Advisor Board | 1M | male |
| Luciano Marraffini | Founder and Member of Scientific Advisor Board | 1M | — |
| John Leonard | President, Chief Executive Officer & Director | 1M | — |
| Edward J. Dulac | Executive Vice President, Chief Financial Officer and Treasurer | 853.7K | male |
| David Lebwohl | Executive Vice President & Chief Medical Officer | 781.4K | — |
| James E. Basta | Executive Vice President, General Counsel & Corporate Secretary | 732.4K | male |
| Birgit Schultes | Executive VP & Chief Scientific Officer | 708.9K | female |
| Michael Dube | VP & Chief Accounting Officer | 478.5K | male |
| Jason Fredette | Vice President of Investor Relations & Corporate Communications | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
| Transaction Date | Disclosed | Senator | State | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2023-08-25 | 2023-09-05 | Thomas R. Carper | DE | Spouse | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2023-05-22 | 2023-06-30 | Thomas R. Carper | DE | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2020-11-20 | 2020-12-02 | Thomas R. Carper | DE | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2018-10-25 | 2018-11-08 | James Inhofe | OK | Self | Sale (Full) | $15,001 - $50,000 | ↗ |
| 2017-10-19 | 2017-11-08 | James Inhofe | OK | Self | Purchase | $15,001 - $50,000 | ↗ |
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2022-02-28 | 2022-03-03 | Donald Sternoff Beyer | VA08 | Joint | Sale (Full) | $15,001 - $50,000 | ↗ |
| 2021-10-29 | 2021-10-30 | Donald Sternoff Beyer | VA08 | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2021-09-20 | 2021-10-01 | Donald Sternoff Beyer | VA08 | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2021-07-21 | 2021-08-07 | Donald Sternoff Beyer | VA08 | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2021-01-15 | 2021-01-31 | Donald Sternoff Beyer | VA08 | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2020-11-18 | 2020-12-01 | Donald Sternoff Beyer | VA08 | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2020-08-26 | 2020-09-06 | Donald Sternoff Beyer | VA08 | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2020-07-10 | 2020-08-09 | Donald Sternoff Beyer | VA08 | Joint | Purchase | $1,001 - $15,000 | ↗ |
| 2020-01-14 | 2020-02-22 | Donald Sternoff Beyer | VA08 | Joint | Purchase | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NTLA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
